AstraZeneca
AZN
1,229 hedge funds and large institutions have $39.1B invested in AstraZeneca in 2024 Q3 according to their latest regulatory filings, with 117 funds opening new positions, 496 increasing their positions, 396 reducing their positions, and 89 closing their positions.
45% more call options, than puts
Call options by funds: $485M | Put options by funds: $334M
31% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 89
25% more repeat investments, than reductions
Existing positions increased: 496 | Existing positions reduced: 396
1% more funds holding
Funds holding: 1,211 → 1,229 (+18)
0% more capital invested
Capital invested by funds: $39B → $39.1B (+$45.6M)
0.03% more ownership
Funds ownership: 16.11% → 16.15% (+0.03%)
11% less funds holding in top 10
Funds holding in top 10: 19 → 17 (-2)
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$808M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$200M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$130M |
| 4 |
D.E. Shaw & Co
New York
|
+$126M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$123M |
Top Sellers
AZN Hedge Fund Activity: Q3 2024 in Review
1,229 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2024, worth a combined $39.1B — up 0.12% from $39B a quarter earlier.
Buyers outnumbered sellers: 117 funds opened new AZN positions and 89 closed out — a net gain of 28 holders — while 496 added to existing stakes and 396 trimmed.
The largest buyer was Bank of America, adding an estimated $808M. The largest seller was Wellington Management Group, cutting an estimated $268M.
- 1,229 institutional investors held AstraZeneca (AZN) as of Q3 2024, up from 1,211 in Q2 2024.
- Funds reported $39.1B of AstraZeneca stock for Q3 2024, up 0.12% quarter-over-quarter.
- 117 funds opened new AstraZeneca positions in Q3 2024 and 89 closed out, a net change of +28 holders.
- The largest AstraZeneca buyer in Q3 2024 was Bank of America, an estimated $808M added.
- The largest AstraZeneca seller in Q3 2024 was Wellington Management Group, an estimated $268M sold.
Based on aggregated 13F filings for Q3 2024.